Double-Targeted CAR-T therapy takes on relapsed blood cancers
NCT ID NCT07523555
First seen Apr 16, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once. It is for adults with blood cancers like leukemia, lymphoma, or myeloma that have come back or not responded to other treatments. The goal is to see if this dual-target approach is safe and works better at killing cancer cells and preventing them from escaping. Up to 96 participants will receive one of eight possible CAR-T cell types based on their cancer's specific markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.